Artwork
iconShare
 
Manage episode 473065375 series 2838329
Content provided by VJHemOnc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJHemOnc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients.

In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, and David Lewis, MD, Plymouth University, Plymouth, UK. The experts cover a variety of topics, exploring the role of BTK inhibitors in R/R MCL, promising combinations being explored, and strategies to overcome resistance.

  continue reading

200 episodes